New cancer drug shows promise in Hard-to-Treat cases
NCT ID NCT05605509
Summary
This study tested a new oral drug called RP-6306, given alongside standard chemotherapy, for people with advanced cancers that had stopped responding to other treatments. Researchers wanted to see if the drug was safe and if it helped shrink tumors, especially in patients whose cancers had specific genetic markers. The trial involved 28 patients with various advanced cancers, including ovarian, pancreatic, and breast cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BCCA - Kelowna
Kelowna, British Columbia, V1Y 5L3, Canada
-
BCCA - Vancouver
Vancouver, British Columbia, V5Z 4E6, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
London Health Sciences Centre Research Inc.
London, Ontario, N6A 5W9, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.